SL PHARM announced that the operating revenue for 2024 is 660 million yuan, a year-on-year decrease of 35.15%. The net profit attributable to shareholders of the listed company is -74.0657 million yuan, a year-on-year decrease of 117.77%. The basic earnings per share is -0.07 yuan/share. The company plans to distribute a cash dividend of 0.2 yuan for every 10 shares to all shareholders, with no bonus shares issued and no capital reserve converted into share capital